Successful completion of the first dose cohort in the study for patients with inoperable bile duct cancer

Oslo, 11 April 2014 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the treatment evaluation of the first dose cohort in the phase I/II study of Amphinex in combination with the cytotoxic agent gemcitabine in patients with inoperable bile duct cancer (cholangiocarcinoma) is completed. No safety concerns were observed at this dose level.A Cohort Review Committee (CRC) of clinical experts and company representatives has been established to evaluate the results and provide recommendation for the continuation of the study. The CRC has recommended that the study progresses into the next dose in accordance with the study protocol. Patients for the next dose cohort are currently being screened and will be treated with Amphinex® as soon as possible.